NCT06674577Phase 2Enrolling by invitation

A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Atacicept

Study sponsor: Vera Therapeutics, Inc. · VERA

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2031-05-21Estimated
Enrollment · participants750Estimated
Source updated2026-06-22Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters

· 2 fields changed

Planned enrollment increased by 274 participants

Before: 476 participants (planned). After: 750 participants (planned).

Primary completion date changed

Before: 31 May 2028. After: 21 May 2031.

Check registry source

Explore older trial changes

Upgrade to Pro to see the full available history for this trial.

Upgrade to Pro Illustrative preview